Stromal CD10 and SPARC expression in ductal carcinoma in situ (DCIS) patients predicts disease recurrence

Agnieszka K. Witkiewicz, Boris Freydin, Inna Chervoneva, Magdalena Potoczek, Wendy Rizzo, Hallgeir Rui, Jonathan R. Brody, Gordon F. Schwartz, Michael P. Lisanti

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

The current classification of ductal carcinoma in situ (DCIS) is based on nuclear grade, architectural differentiation and the presence of necrosis that does not adequately predict the likelihood of recurrence after breast conserving therapy; therefore, there is a critical need to identify novel predictors of DCIS progression. Ninety seven cases of DCIS were included in the study. CD10 and SP ARC expression in tumor stroma was assessed by standard immunoperoxidase method with ani-CD 10 and anti-SP ARC antibodies. The staining was scored semi-quantitatively as negative, weak or strong. Statistical analysis was performed using the Fisher's exact test. Multivariable analysis was conducted utilizing Exact Logistic Regression software (SAS 9.1 and LogExact). A significant association was observed between the recurrence status and time to recurrence with expression of CD10 (p < 0.001) and SP ARC (p < 0.001). When combining both SP ARC and CD10 expression there was a strong correlation with the shortest time to recurrence. Stromal CD10 and SP ARC expression are new markers of an increased risk for DCIS recurrence, independent of commonly assessed clinical parameters. Thus, stromal CD10 and SP ARC expression levels are promising markers of DCIS recurrence and warrant evaluation in larger prospective studies.

Original languageEnglish (US)
Pages (from-to)391-396
Number of pages6
JournalCancer Biology and Therapy
Volume10
Issue number4
DOIs
StatePublished - Aug 15 2010

Fingerprint

AIDS-Related Complex
Carcinoma, Intraductal, Noninfiltrating
Recurrence
Anal Canal
Breast
Necrosis
Software
Logistic Models
Prospective Studies
Staining and Labeling
Antibodies
Neoplasms

Keywords

  • Cancer stroma
  • CD10
  • DCIS
  • SPARC

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Molecular Medicine
  • Pharmacology

Cite this

Stromal CD10 and SPARC expression in ductal carcinoma in situ (DCIS) patients predicts disease recurrence. / Witkiewicz, Agnieszka K.; Freydin, Boris; Chervoneva, Inna; Potoczek, Magdalena; Rizzo, Wendy; Rui, Hallgeir; Brody, Jonathan R.; Schwartz, Gordon F.; Lisanti, Michael P.

In: Cancer Biology and Therapy, Vol. 10, No. 4, 15.08.2010, p. 391-396.

Research output: Contribution to journalArticle

Witkiewicz, AK, Freydin, B, Chervoneva, I, Potoczek, M, Rizzo, W, Rui, H, Brody, JR, Schwartz, GF & Lisanti, MP 2010, 'Stromal CD10 and SPARC expression in ductal carcinoma in situ (DCIS) patients predicts disease recurrence', Cancer Biology and Therapy, vol. 10, no. 4, pp. 391-396. https://doi.org/10.4161/cbt.10.4.12449
Witkiewicz, Agnieszka K. ; Freydin, Boris ; Chervoneva, Inna ; Potoczek, Magdalena ; Rizzo, Wendy ; Rui, Hallgeir ; Brody, Jonathan R. ; Schwartz, Gordon F. ; Lisanti, Michael P. / Stromal CD10 and SPARC expression in ductal carcinoma in situ (DCIS) patients predicts disease recurrence. In: Cancer Biology and Therapy. 2010 ; Vol. 10, No. 4. pp. 391-396.
@article{2296c6f565bd4500940c63114b3abd72,
title = "Stromal CD10 and SPARC expression in ductal carcinoma in situ (DCIS) patients predicts disease recurrence",
abstract = "The current classification of ductal carcinoma in situ (DCIS) is based on nuclear grade, architectural differentiation and the presence of necrosis that does not adequately predict the likelihood of recurrence after breast conserving therapy; therefore, there is a critical need to identify novel predictors of DCIS progression. Ninety seven cases of DCIS were included in the study. CD10 and SP ARC expression in tumor stroma was assessed by standard immunoperoxidase method with ani-CD 10 and anti-SP ARC antibodies. The staining was scored semi-quantitatively as negative, weak or strong. Statistical analysis was performed using the Fisher's exact test. Multivariable analysis was conducted utilizing Exact Logistic Regression software (SAS 9.1 and LogExact). A significant association was observed between the recurrence status and time to recurrence with expression of CD10 (p < 0.001) and SP ARC (p < 0.001). When combining both SP ARC and CD10 expression there was a strong correlation with the shortest time to recurrence. Stromal CD10 and SP ARC expression are new markers of an increased risk for DCIS recurrence, independent of commonly assessed clinical parameters. Thus, stromal CD10 and SP ARC expression levels are promising markers of DCIS recurrence and warrant evaluation in larger prospective studies.",
keywords = "Cancer stroma, CD10, DCIS, SPARC",
author = "Witkiewicz, {Agnieszka K.} and Boris Freydin and Inna Chervoneva and Magdalena Potoczek and Wendy Rizzo and Hallgeir Rui and Brody, {Jonathan R.} and Schwartz, {Gordon F.} and Lisanti, {Michael P.}",
year = "2010",
month = "8",
day = "15",
doi = "10.4161/cbt.10.4.12449",
language = "English (US)",
volume = "10",
pages = "391--396",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "4",

}

TY - JOUR

T1 - Stromal CD10 and SPARC expression in ductal carcinoma in situ (DCIS) patients predicts disease recurrence

AU - Witkiewicz, Agnieszka K.

AU - Freydin, Boris

AU - Chervoneva, Inna

AU - Potoczek, Magdalena

AU - Rizzo, Wendy

AU - Rui, Hallgeir

AU - Brody, Jonathan R.

AU - Schwartz, Gordon F.

AU - Lisanti, Michael P.

PY - 2010/8/15

Y1 - 2010/8/15

N2 - The current classification of ductal carcinoma in situ (DCIS) is based on nuclear grade, architectural differentiation and the presence of necrosis that does not adequately predict the likelihood of recurrence after breast conserving therapy; therefore, there is a critical need to identify novel predictors of DCIS progression. Ninety seven cases of DCIS were included in the study. CD10 and SP ARC expression in tumor stroma was assessed by standard immunoperoxidase method with ani-CD 10 and anti-SP ARC antibodies. The staining was scored semi-quantitatively as negative, weak or strong. Statistical analysis was performed using the Fisher's exact test. Multivariable analysis was conducted utilizing Exact Logistic Regression software (SAS 9.1 and LogExact). A significant association was observed between the recurrence status and time to recurrence with expression of CD10 (p < 0.001) and SP ARC (p < 0.001). When combining both SP ARC and CD10 expression there was a strong correlation with the shortest time to recurrence. Stromal CD10 and SP ARC expression are new markers of an increased risk for DCIS recurrence, independent of commonly assessed clinical parameters. Thus, stromal CD10 and SP ARC expression levels are promising markers of DCIS recurrence and warrant evaluation in larger prospective studies.

AB - The current classification of ductal carcinoma in situ (DCIS) is based on nuclear grade, architectural differentiation and the presence of necrosis that does not adequately predict the likelihood of recurrence after breast conserving therapy; therefore, there is a critical need to identify novel predictors of DCIS progression. Ninety seven cases of DCIS were included in the study. CD10 and SP ARC expression in tumor stroma was assessed by standard immunoperoxidase method with ani-CD 10 and anti-SP ARC antibodies. The staining was scored semi-quantitatively as negative, weak or strong. Statistical analysis was performed using the Fisher's exact test. Multivariable analysis was conducted utilizing Exact Logistic Regression software (SAS 9.1 and LogExact). A significant association was observed between the recurrence status and time to recurrence with expression of CD10 (p < 0.001) and SP ARC (p < 0.001). When combining both SP ARC and CD10 expression there was a strong correlation with the shortest time to recurrence. Stromal CD10 and SP ARC expression are new markers of an increased risk for DCIS recurrence, independent of commonly assessed clinical parameters. Thus, stromal CD10 and SP ARC expression levels are promising markers of DCIS recurrence and warrant evaluation in larger prospective studies.

KW - Cancer stroma

KW - CD10

KW - DCIS

KW - SPARC

UR - http://www.scopus.com/inward/record.url?scp=77956408178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956408178&partnerID=8YFLogxK

U2 - 10.4161/cbt.10.4.12449

DO - 10.4161/cbt.10.4.12449

M3 - Article

VL - 10

SP - 391

EP - 396

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 4

ER -